We used the method of Rudolph et al. (Clin Chem 1988; 34:2031-8) to find information in the data from correlated determinations of acid phosphatase (PAP, EC 3.1.3.2; DuPont aca) and prostate-specific antigen (PSA, Hybritech). We described there how we assign medical decision limitsfor two or more correlated variables and convert the database to a binary coded message, allowing separation of a selected disease class with minimum error. The decision point, analogous to a percentile upper limit on the ordered values of each variable in the reference group, satisfies the maximum entropy constraints of reference, producing a minimum entropy for the binary coded patient database. We found maximum entropy decision points at PAP = 0. Since the description of prostate-specific antigen (PSA), a prostatic epithelial glycoprotein and kallikrein acting as a serine protease on the seminal vesical coagulum (1, 2) , several papers have demonstrated its value as a potential marker in serum of patients with prostatic cancer.4 This test was found in early studies to have a mean concentration in serum proportional to the clinical stage of carcinoma (3). Also, the measured concentrations of PSA correspond to the disease-free interval after treatment (4). Moreover, PSA is more sensitive than prostatic acid phosphatase (PAP; EC 3.1.3.2) for detection of recurrent carcinoma and for monitoring therapy, because the concentration of PSA increases before there are clinical signs of relapse (4) (5) (6) .
Since the description of prostate-specific antigen (PSA), a prostatic epithelial glycoprotein and kallikrein acting as a serine protease on the seminal vesical coagulum (1, 2) , several papers have demonstrated its value as a potential marker in serum of patients with prostatic cancer. 4 This test was found in early studies to have a mean concentration in serum proportional to the clinical stage of carcinoma (3) . Also, the measured concentrations of PSA correspond to the disease-free interval after treatment (4) . Moreover, PSA is more sensitive than prostatic acid phosphatase (PAP; EC 3.1.3.2) for detection of recurrent carcinoma and for monitoring therapy, because the concentration of PSA increases before there are clinical signs of relapse (4) (5) (6) .
In this study we examined the use of PSA and PAP Analysis. We used the method of Rudolph et al. (7) to determine which values for PAP and PSA in serum divide the population into reference and disease subsets, similar to the definition of an upper limit of normal. Using only the population data at hand, we determined the decision limits for PSA and PAP that optimally classified patients with the least misclassification of adenocarcinoma when prostatitis and BPH contribute mostly to misclassification error rates. We also carried out such standard statistical studies as ANOVA2, Kruskal-Wallis analysis, and histogram plots, using "stsc statgraphics" software (stsc, Rockville, MD).
Group-based
reference. The optimum decision levels for PSA and PAP are measured by using Shannon entropy. The basic measure of missing information is as described (3):
where H is entropy (the average information of a message set), and P is the probability of a choice from a set of messages. The results referred to these decision values (cutoff limits) were converted to a binary code. We used the Bernoulli trial to determine maximum entropy reference. In the reference or normal population, the entropy of all possible binary patterns approaches 2 bits as the number of observations increases (7) . Because no information is present in this population, the measured uncertainty is maximum and the probability distribution is flat. The probability distribution of the binary patterns is not flat when there is effective information in the data, which results in a drop in entropy. We create a flat probability distribution by randomly shuffling the variables and destroying the information in the data. The distribution is not flat if information is present because of correlation in the data. The frequency distributions we refer to are an all-negative pattern, 00, an all-positive pattern, 11, and intermediate patterns, 01 and 10. The difference between the measured entropy of the database and the randomization maximum entropy reflects the effective information present. This difference, an effective information maximum at PSA = 22.8 ng/mL, is plotted in Figure 1 .
The value for any variable at which this difference is greatest is the optimum decision point for the variable used in the classification. 
Results
The method to which we refer (7) does not depend on establishing a normal range for a low-prevalence population. It allows us to define and differentiate patients with carcinoma in a disease population, when in nondisease PSA values are <3.5 nglmL, but there is a large disease population with nonmalignant diagnoses at higher values for PSA. To eliminate this problem, we use the mutual dependency of the PSA and PAP to effectively identify the malignant disease population, using the entire population for evaluation. The PAP had a single decision value, 0.75 U/L. The PSA has two major decision values, 54.6 and 22.8 ng/mL, and additional information peaks at 11.3 and 3.5 ng/mL.
The decision value at PSA 22.8 ng/mL mainly separates adenocarcinoma of the prostate-stages B, C, and D-from a subpopulation with a 60.6% frequency of BPH and prostatitis. At 54.6 ng/mL, we eliminated four of five patients with benign PSA increases within the population >22.8 nglmL who are selected for prostatic adenocarcinoma (Table 2). A PSA value of 11.3 to 22.8 ng/mL may be equivocal. It is not possible to distinguish carcinoma of prostate from other diagnoses in this range by use of any PSA value. The median PSA value for 13 patients with other disease is 14.4 ng/mL.
In addition, we reviewed 94 specimens from patients in the benign group with disease other than carcinoma of the prostate and found that 71 (75.5%) had PSA values <10 ng/mL and, of 17 cases of nonprostatic carcinoma, all had PSA <5 ng/mL. We used a decision value of 22.8 ng/mL, which defines the upper confidence limit for distinguishing the disease population of interest in the same way as upper limits of normal, to cluster the population with a PAP of 0.75 UIL as a covariant test. We did this by using the binary equivalent assignments, 0 or 1, to each of the paired values of PSA and PAP, based on whether the assigned decision value is exceeded or not, and examining the frequency distribution of carcinoma against the classification formed. The result was the pattern shown in Table 3 .
Only one of 13 patients with above-normal PAP without increased PSA had adenocarcinoma of the prostate. Consequently, a value for PSA >22.8 ng/mL, with or without increased PAP, is required to identify significant risk of adenocarcinoma of the prostate, and at such values it appears usually to be associated with stage C or D disease. Table 4, a reorganized Table 3 , defines the occurrence of binary class patterns with respect to carcinoma of the prostate by stage compared with nondisease. The table allows the estimation of 87.8% sensitivity, 79% specificity, a negative predictive value of 97.1%, and a positive predictive value of 44.4% for PSA >22.8 ng/mL. Tables 5 and 6 
Discussion
Here we have used the method of Rudolph et al. (7) to find information in the data based on the mutual dependence of or prostatitis. The distinction was almost absolute for PSA >54.6 ng/mL. The maximum entropy decision point at 54.6 ng/mL was consistent with studies showing mean PSA concentrations of 223 ng/mL with confidence intervals from 141 to 305 ng/mL for stages B, C, or D adenocarcinoma. This is consistent with findings of stage C and D adenocarcinoma having PSA >85 ng/mL (8, 9) . Another decision point occurs at 11.3 ng/mL. This defines the equivocal region between 11.3 and 22.8 ng/mL, where the incidence of carcinoma of the prostate is 39%. At <11.3 ng/mL there is a high frequency of BPH, and when PSA is <3.5 ng/mL there usually is no disease. A PSA value <10 ng/mL has no information. Further, at this concentration a metastatic carcinoma is as likely to be nonprostatic as prostatic. These studies establish the importance of a PSA value >22.8 ng/mL as a basis for careful evaluation for adenocarcinoma of the prostate. Further, these studies reinforce the findings of Seamonds et al. (8) suggesting the sensitivity of PSA values >11.3 ng/mL, despite the inconclusiveness of such a finding because of the high frequency of BPH and prostatitis. Another diagnostic test in combination with PSA other than PAP would be necessary to relieve the uncertainty when PSA is between 11.3 and 22.8 ng/mL.
